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Modification of single-nucleotide 
polymorphism in a fully humanized 
CYP3A mouse by genome editing 
technology
Satoshi Abe1, Kaoru Kobayashi2, Asami Oji3, Tetsushi Sakuma4, Kanako Kazuki1, Shoko 
Takehara1, Kazuomi Nakamura5, Azusa Okada2, Yasuko Tsukazaki6, Naoto Senda1,6, Kazuhisa 
Honma7, Takashi Yamamoto4, Masahito Ikawa  3, Kan Chiba2, Mitsuo Oshimura1 & Yasuhiro 
Kazuki1,7
Cytochrome P450, family 3, subfamily A (CYP3A) enzymes metabolize approximately 50% of 
commercially available drugs. Recently, we developed fully humanized transchromosomic (Tc) CYP3A 
mice with the CYP3A cluster including CYP3A4, CYP3A5, CYP3A7, and CYP3A43. Our humanized 
CYP3A mice have the CYP3A5*3 (g.6986G) allele, resulting in the almost absence of CYP3A5 protein 
expression in the liver and intestine. To produce model mice for predicting CYP3A5′s contribution 
to pharmacokinetics, we performed a single-nucleotide polymorphism (SNP) modification of 
CYP3A5 (g.6986G to A, *3 to *1) on the CYP3A cluster using genome editing in  both mouse ES cells 
and fertilized eggs, and produced humanized CYP3A5*1 mice recapitulating the CYP3A5*1 carrier 
phenotype in humans. The humanized CYP3A mouse with CYP3A5*1 is the first Tc mouse for predicting 
the SNP effect on pharmacokinetics in humans. The combination of Tc technology and genome editing 
enables the production of useful humanized models that reflect humans with different SNPs.
Cytochrome P450, family 3, subfamily A (CYP3A) is a group of drug-metabolizing enzymes that metabolize 
approximately 50% of commercially available drugs. Therefore, in the field of drug development, the contribution 
of CYP3A in pharmacokinetics of new chemical entities has to be evaluated. In conventionally used experimental 
animals, such as mice and rats, the conditions do not completely reflect the human pharmacokinetics of drugs 
metabolized by CYP3A. It is well known that substantial species differences exist in CYP3A enzymes1. Therefore, 
we developed a humanized transchromosomic (Tc) CYP3A mouse models based on human artificial chromo-
some (HAC) and mouse artificial chromosome (MAC) vectors using chromosome engineering technology.
CYP3A genes are clustered together on human chromosome 7 and include CYP3A4, CYP3A5, CYP3A7, 
and CYP3A43. We cloned 700 kilobases, including the CYP3A cluster on human chromosome 7, into the 
HAC vector (CYP3A-HAC) and transferred the CYP3A-HAC into mouse embryonic stem (ES) cells via 
microcell-mediated chromosome transfer (MMCT). We produced humanized mice carrying the CYP3A-HAC 
with a mouse-Cyp3a-knockout (KO) background. Our models recapitulated the gender-, tissue-, and 
developmental-stage-specific CYP3A expression and the CYP3A-related drug metabolism in humans2–4. 
Recently, we generated novel fully humanized CYP3A (CYP3A-MAC) mice with almost same characteristics 
1Chromosome Engineering Research Center (CERC), Tottori University, 86 Nishi-cho, Yonago, Tottori, 683-8503, 
Japan. 2Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8675, 
Japan. 3Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, 565-0871, Japan. 4Department of 
Mathematical and Life Sciences, Graduate School of Science, Hiroshima University, Higashi, Hiroshima, 739-8526, 
Japan. 5Division of Laboratory Animal Science, Research Center for Bioscience and Technology, Tottori University, 
86 Nishi-cho, Yonago, Tottori, 683-8503, Japan. 6Tsukuba Bioanalytical Laboratory, Shin Nippon Biomedical 
Laboratories, Ltd., 2-1-6 Sengen, Tsukuba, Ibaraki, 305-0047, Japan. 7Department of Biomedical Science, Institute 
of Regenerative Medicine and Biofunction, Graduate School of Medical Sciences, Tottori University, 86 Nishi-cho, 
Yonago, Tottori, 683-8503, Japan. Correspondence and requests for materials should be addressed to Y.K. (email: 
kazuki@grape.med.tottori-u.ac.jp)
Received: 24 July 2017
Accepted: 19 October 2017
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2Scientific RepORts | 7: 15189  | DOI:10.1038/s41598-017-15033-0
with the CYP3A-HAC mice excepting the stability of the exogenous chromosome by using a MAC vector which 
is more stably maintained in mice than the HAC5,6 (Kazuki Y. et al., unpublished data).
Studies on the contributions of CYP3A enzymes to pharmacokinetics have mainly focused on CYP3A4 in 
adults. CYP3A7 expressed in fetuses is gradually replaced by CYP3A4 after birth7,8. Although little is known 
about the function of CYP3A43, the importance of the contributions of other CYP3As to pharmacokinetics, 
particularly CYP3A5, should also be considered. Despite CYP3A5 being highly similar to CYP3A4 at the amino 
acid level, the degrees of catalytic capability and regioselectivity toward some substrates are different9–11. CYP3A5 
genotypes are associated with the dosing condition of many drugs, such as tacrolimus, which is a well-known 
immune suppressor used for organ transplantation12,13. Moreover, it has been reported that CYP3A5 contrib-
utes to therapy resistance in different subtypes of pancreatic ductal carcinoma14. Therefore, the contribution of 
CYP3A5 to drug metabolism and the mechanism of expression of CYP3A5 have been re-evaluated recently.
CYP3A5 single-nucleotide polymorphisms (SNPs) have been known to affect CYP3A5 expression. Among 
various SNP alleles of the CYP3A5 gene that have been reported, the most well-studied ones are CYP3A5*1 
(6986A) and CYP3A5*3 (g.6986A > G)15–17. SNP associated with these alleles is located in intron 3 of CYP3A5. 
Carriers of the CYP3A5*1 allele express the CYP3A5 protein, while homozygotes of the CYP3A5*3 allele show a 
splicing defect resulting in the absence of CYP3A5 protein expression. It has been reported that 10–30% of adult 
Caucasians and Asians express detectable amounts of CYP3A5, whereas 60% of African-Americans do so. Taking 
these findings together, the prediction of CYP3A5-related drug pharmacokinetics in both CYP3A5 expressers 
and non-expressers is very important. Humanized model animals are thought to be useful in pursuit of this goal. 
However, the CYP3A5 genotype of our humanized CYP3A model mice was CYP3A5*3, which was associated 
with undetectable protein expression in the liver and very low protein expression in the intestine. Therefore, the 
contribution of CYP3A5 could not be evaluated in this model. Although there are compounds metabolized by 
both CYP3A4 and CYP3A5, the extent to which CYP3A5 contributes to the metabolism of such substrates in vivo 
remains unclear. Thus, a model that expresses both CYP3As, CYP3A4 and CYP3A5, is expected to be useful in 
the validation of contribution. To confirm the contribution of human CYP3A5 to drug metabolism using a model 
mouse, the development of a model harboring the human CYP3A5*1(6986A) allele was desired.
Recently, genome editing technologies, such as zinc-finger nuclease, transcription activator-like effector 
nuclease, and clustered regularly interspaced short palindromic repeats/Crispr associated protein 9 (CRISPR/
Cas9), have provided more efficient options to modify a targeted sequence for the production of KO or knock-in 
(KI) cells and animals18. These technologies generate DNA double-strand breaks (DSBs). DSBs are repaired by 
either non-homologous end joining or homology-directed repair (HDR) machinery. An error in the repair pro-
cess disrupts the targeted gene or sequence, resulting in the production of KO cells and organisms. If DSBs are 
induced in the presence of double-stranded or single-stranded donor DNA with a homologous sequence, we can 
obtain KI cells and animals or achieve the desired modification of the sequence. Currently, the CRISPR/Cas9 
system is the most convenient tool for making desired modifications to targeted sequences.
In the present study, we produced humanized CYP3A5*1 mice by modifying the CYP3A5*3 SNP on the 
CYP3A-MAC using genome editing technology, namely, the CRISPR/Cas9 system. We successfully modified 
CYP3A5*3 SNP to CYP3A5*1 (6986G to A) in both mouse ES cells (ESC-transfection) and fertilized eggs (pronu-
clear injection), for which the modification efficiencies were high. Expression of the CYP3A5 protein in the liver 
and intestine was higher in humanized CYP3A5*1 mice than in CYP3A5*3 mice. The contribution of CYP3A5 
was also evaluated by inhibition assays, and higher CYP3A5 enzymatic activity was detected in the liver and intes-
tinal microsomes of CYP3A5*1 mice than in those of CYP3A5*3 mice. The humanized CYP3A (CYP3A5*1) 
mice are useful for evaluating the contribution of human CYP3A5 to drug screening and for understanding the 
mechanism of CYP3A5 gene expression.
Results
Validation of CRISPR/Cas9 gRNA for targeted cleavage. Previously, we generated CYP3A-HAC 
mouse using the HAC vector. Recently, we successfully generated CYP3A-MAC and Tc mice with CYP3A-MAC 
via mouse ES cells (the manuscript is in preparation). Because the MAC is more stably maintained in mice than 
the HAC, we utilized the CYP3A-MAC in mouse ES cells and fertilized eggs in the present study.
The CYP3A5 genotype on the CYP3A cluster was CYP3A5*3, as described previously2. To modify CYP3A5 
SNP on the CYP3A-MAC, we adapted an HDR-mediated modification strategy using the CRISPR/Cas9 system 
in both mouse ES cells and fertilized eggs (Fig. 1A). In this strategy, cleavage of the target site by the CRISPR/Cas9 
system will activate the DNA repair machinery, and HDR-mediated SNP modification will occur in the presence 
of the donor plasmid or single-stranded oligodeoxynucleotide (ssODN), with a homology sequence harboring 
the desired SNP. We utilized the pX330 plasmid expressing the Cas9 protein and gRNA for genome editing19.
Two target sequences were chosen and two pX330 plasmids were constructed (Fig. 1B). The cleavage activity 
was first validated using a luciferase gene reconstruction-based single-strand annealing (SSA) assay20. The gRNA 
targeting CYP3A5_B (pX330-B) showed higher activity than that targeting CYP3A5_A (pX330-A) (data not 
shown). Next, specific on-target cleavage was evaluated using the pCAG-EGxxFP-based SSA assay because a high 
homology potential off-target sequence exists in other CYP3A genes (CYP3A4, CYP3A7, and CYP3A43) on the 
CYP3A-MAC (Supplementary Fig. 1)21.
The pCAG-EGxxFP plasmid comprises 5′EGFP and 3′EGFP sequences with some overlap between them. 
The target sequence is inserted between 5′EGFP and 3′EGFP. When the pCAG-EGxxFP-target and pX330-gRNA 
are co-transfected into culture cells and pX330-sgRNA has the ability to cleave the target sequence, the cleaved 
EGxxFP-target is repaired by either homologous recombination or SSA, resulting in EGFP reconstitution. 
Therefore, the cleavage activity can be validated by detecting the number of EGFP-positive cells and the intensity 
of the EGFP fluorescence signal.
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The pCAG-EGxxFP assay revealed that pX330-B has off-target effects on other CYP3A sequences, particu-
larly CYP3A7 and CYP3A4, whereas pX330-A displays specific on-target activity only to CYP3A5, without any 
off-target effects on other CYP3A genes (Fig. 2A). Further analysis was performed on whether pX330-A has the 
ability to cleave the modified sequence. If it does, the efficiency of the desired modification would be expected 
to be lower. However, pX330-A did not show any activity toward the expected modified sequence with a 1-bp 
mismatch (Fig. 2B). Considering these results, we chose to use pX330-A for SNP modification.
SNP modification in mouse ES cells carrying the CYP3A-MAC and CYP3A5*1 mouse production. 
To produce humanized CYP3A5*1 mice, we performed SNP modification of the CYP3A-MAC in mouse ES 
cells as described previously22. As a donor for the SNP modification of CYP3A5 in mouse ES cells containing 
CYP3A-MAC, we employed a plasmid comprising a 500-bp homology arm L, SNP, and a 500-bp homology arm R 
(HA plasmid) (Fig. 3A). We co-transfected pX330-A with HA plasmids and analyzed 64 clones by PCR-restriction 
fragment length polymorphism (PCR-RFLP) for CYP3A5 SNP (Fig. 3B and Supplementary Fig. 2). In total, 12 of 
64 clones (18.8%) showed only the CYP3A*1 genotype. The others mainly showed a mixture of cells having the 
CYP3A5*1 or CYP3A5*3 genotype and a clone without modification (CYP3A5*3). By direct sequencing, we con-
firmed six clones (9%) with the exact modification of the CYP3A5*1 sequence on the CYP3A-MAC (designated 
as CYP3A5*1-MAC). Further genomic PCR analyses revealed that other CYP3A genes on the CYP3A-MAC were 
not disrupted (Fig. 3C and Supplementary Fig. 4). Karyotype analysis confirmed that all six clones had a nor-
mal karyotype with independent CYP3A5*1-MAC at a high rate (Fig. 3D). Following this, we produced chi-
meric mice by injecting mouse ES cells carrying the CYP3A5*1-MAC. The chimeric mice were crossed with 
mouse-Cyp3a-KO mice, and germline transmission of the CYP3A5*1-MAC was confirmed. Further crossing 
with mouse-Cyp3a-KO mice eventually produced humanized CYP3A5*1 mice with a Cyp3a-KO background 
(designated as CYP3A5*1 mouse).
SNP modification in fertilized eggs carrying the CYP3A-MAC and CYP3A5*1 mouse production. 
For modification of CYP3A5 SNP, we performed genome editing of the CYP3A-MAC in fertilized eggs. ICR 
female and male mice carrying the CYP3A-MAC were mated, and then the fertilized eggs were obtained. 
pX330-A and ssODNs (135 bp containing A) were co-injected into the fertilized eggs (Fig. 4A). Nine mice with 
GFP positivity (9 of 27; 33%), indicating the presence of the CYP3A-MAC, were obtained. PCR-RFLP analysis 
showed one mouse (1 of 9; 11%) having cells with CYP3A5*1 or CYP3A5*3, implying mosaicism (Fig. 4B and 
Supplementary Fig. 3). Other mice had the CYP3A5*3 genotype (Fig. 4B and Supplementary Fig. 3). The mouse 
with potential CYP3A5 mosaicism was mated with a mouse-Cyp3a-KO mouse, from which five GFP-positive 
Figure 1. Strategy of humanized CYP3A5*1 mouse production and the design of the target for SNP 
modification. (A) Schematic diagram of humanized CYP3A5*1 mouse development. SNP of CYP3A5 on the 
CYP3A-MAC was modified in both mouse ES cells and fertilized eggs. Mice with the CYP3A*1-MAC were 
mated with mouse-Cyp3a-KO mice, and humanized CYP3A5*1 mice were produced. (B) The map of CYP3A5 
SNP locus. CYP3A5*1 and CYP3A5*3 sequence and CRISPR/Cas9 targeting sites, CYP3A5_A and CYP3A5_B, 
are underlined. Red characters show SNPs and red rectangles indicate PAM sequences.
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Figure 2. Validation of cleavage activity by the pCAG-EGxxFP system. (A) pCAG-EGxxFP assay results for 
pX330-A and pX330-B activity in the CYP3A5 region and other off-target sites of each CYP3A region. GFP 
intensity and GFP-positive cells display the activity. (B) pCAG-EGxxFP assay results of pX330-A for validation 
of the cleavage activity toward the modified sequence. P: positive control with pX330-gRNA and pCAG-
EGxxFP-target. N: negative control with pX330 empty and pCAG-EGxxFP-target.
Figure 3. CYP3A5 SNP modification in mouse ES cells carrying the CYP3A-MAC. (A) Schematic diagram of 
CYP3A5 SNP modification in mouse ES cells. The pX330-A plasmid and a plasmid with CYP3A5 *1 SNP and 
each homologous arm of about 500 bp were co-transfected into mouse ES cells carrying the CYP3A-MAC.  
(B) Representative PCR-RFLP assay result. Each sample was numbered. The upper 129-bp and lower 107-bp 
bands indicate *1 allele and *3 allele, respectively. Red circles indicate candidates. H: human DNA sample with 
both *1 and *3 alleles as a control. (C) Genomic PCR results for the CYP3A region in sequence-positive (*1 
allele) clones. (D) FISH analysis result of mouse ES cells carrying the CYP3A5*1-MAC. The arrowhead shows 
the CYP3A5*1-MAC, indicated in red. The inset displays an enlarged image of the CYP3A5*1-MAC.
www.nature.com/scientificreports/
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offspring were obtained. Fortunately, PCR-RFLP analysis revealed that three of these five mice had the CYP3A5*1 
genotype and the other mice had the CYP3A5*3 genotype (Fig. 4C and Supplementary Fig. 5). These results 
suggest that the mouse obtained by injection did indeed exhibit mosaicism. To avoid random integration, direct 
sequencing was performed with primers that amplify a wider region of the homologous sequence for SNP mod-
ification. Direct sequencing using the genome of the tail of F1 mice as a template revealed the precise SNP mod-
ification without any other sequence rearrangement around the CRISPR/Cas9 target site (data not shown). We 
also obtained a positive result in further genomic PCR for other CYP3As (Fig. 4D and Supplementary Fig. 4). 
The mice carrying the CYP3A-MAC with CYP3A5*1 were further mated with mouse-Cyp3a-KO mice, leading 
to the eventual production of a humanized CYP3A5*1 mouse. The humanized CYP3A5*1 mice generated via 
pronuclear injection were used in following studies.
CYP3A5 protein expression in the liver and intestine of CYP3A5*1 mice. To determine the pro-
tein expression of human CYP3A derived from the CYP3A5*1 mice, an LC-MS/MS-based assay was performed. 
CYP3A4 expression in the liver and intestine was comparable between CYP3A5*3 and CYP3A5*1 mice (Fig. 5A). 
However, the amount of CYP3A5 protein in the liver and intestine was significantly higher in CYP3A5*1 mice 
than in CYP3A5*3 mice (Fig. 5B). These findings suggested that CYP3A5 SNP modification increased the expres-
sion of the CYP3A5 protein.
Metabolic activity of CYP3A in the liver and intestine of CYP3A5*1 mice. Triazolam is a widely 
used substrate for assessing the contribution of CYP3A4 and CYP3A5 activity to metabolism23–26. To investigate 
the function of the CYP3A gene in CYP3A5*1 mice, triazolam alpha-hydroxylation activities were analyzed in 
the liver and intestine of CYP3A5*1 mice. In both liver and intestinal microsomes of CYP3A5*1 mice, apparent 
activities were detected, which contrasted to the very low levels or absence of activity in mouse-Cyp3a-KO mice 
(Fig. 6A and B). These findings suggested that CYP3A genes in CYP3A5*1 mice are functional and not disrupted 
by off-target effects via genome editing.
Inhibition assay for the validation of CYP3A5 contribution. CYP3A5 activity should be confirmed 
to check whether the functional CYP3A5 protein is expressed in CYP3A5*1 mice. However, it has been reported 
that there is no apparent difference in substrate specificity between CYP3A4 and CYP3A527. In addition, no 
potent and selective CYP3A5 inhibitors have been identified. Thus, CYP3A4/3A5 and CYP3A4 inhibition assays 
were conducted to estimate the functional contribution of the CYP3A5 protein to triazolam alpha-hydroxylation, 
in accordance with a previously reported method23. Ketoconazole was used as an inhibitor of both CYP3A4 and 
CYP3A5, and CYP3cide was used as a selective inhibitor of CYP3A4. As shown in Fig. 7A and B, ketoconazole 
and CYP3cide inhibited the activities in the liver microsomes of CYP3A5*1 (76.8% and 31.2% inhibition, respec-
tively) and CYP3A5*3 mice (71.9% and 41.9% inhibition, respectively). In the intestinal microsomes, the activi-
ties of both CYP3A5*1 and CYP3A5*3 mice were completely inhibited by ketoconazole (Fig. 7C), but the percent 
inhibitions by CYP3cide of the activities of CYP3A5*1 mice were smaller than those of CYP3A5*3 mice (43.9% 
Figure 4. CYP3A5 SNP modification in fertilized eggs with the CYP3A-MAC by pronuclear injection and 
the germline transmission of the CYP3A5*1-MAC. (A) Schematic diagram of CYP3A5 SNP modification in 
fertilized eggs. pX330-A and ssODN with *1 SNP and short homologous arms were injected into fertilized eggs 
with the CYP3A-MAC. (B) PCR-RFLP assay result of F0 mice for CYP3A5 SNP genotyping. (C) PCR-RFLP 
assay result of F1 mice. (D) Genomic PCR analysis results of the parent mosaic F0 mouse and F1 mice carrying 
the CYP3A5*1-MAC. N: WT mouse DNA. P: DNA derived from mouse with the CYP3A5*3-MAC. H: human 
DNA sample with both *1 and *3 alleles as a control.
www.nature.com/scientificreports/
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and 66.5% inhibition, respectively, Fig. 7D). When the percent contributions of CYP3A5 protein to triazolam 
alpha-hydroxylation activities were estimated by subtracting the percent inhibition by CYP3cide (% CYP3A4 
contribution) from the percent inhibition by ketoconazole (% CYP3A contribution), a significant CYP3A5 con-
tribution was identified in both liver and intestinal microsomes derived from CYP3A5*1 mice (Fig. 7E). These 
results suggested that functional CYP3A5 protein and higher CYP3A5 activity are exhibited in CYP3A5*1 mice 
compared with CYP3A5*3 mice. These findings together show that CYP3A5*1 mice, developed by genome edit-
ing technology, can act as a model recapitulating a human CYP3A5*1 carrier.
Discussion
In the present study, we successfully performed SNP modification using genome editing technology in both 
mouse ES cells and fertilized eggs, and produced mice with different SNPs. Humanized mouse models for analyz-
ing the effect of SNPs have been reported, such as for TP53, the effect of an SNP of which was revealed in bacterial 
artificial chromosome (BAC) transgenic mice28. However, the BAC transgenic system has several potential prob-
lems in copy number control, integration site effect, and limitation of genomic size to transfer to cells. The MAC 
vector system solves these problems, with advantages such as desired copy delivery, independent maintenance 
without integration to the host genome, and no genome size limitation to deliver. The MAC vector system allows 
us to transfer one copy (one allele) of a gene or genome into animals; it should enable the effects of polymor-
phisms of the transferred human genomes to be clearly observed.
Because the coordinated expressions of CYP3A4 and CYP3A5 affect metabolic function, the expression of 
both in mice is necessary for the prediction of drug metabolism in humans with CYP3A5*1 allele. Thus, the 
modification of the CYP3A-MAC carrying both CYP3A4 and CYP3A5 genomic regions was best suited for this 
study. The comparison of CYP3A5*1 and CYP3A5*3 mice is expected to allow us to validate the contribution of 
Figure 5. Protein quantitative analysis of CYP3A5*1 mice. (A) LC-MS/MS analysis results for CYP3A4 
protein quantity in the liver and intestine of humanized CYP3A5*3(*3) and CYP3A5*1(*1) mice. (B) LC-MS/
MS analysis results for CYP3A5 protein quantity in the liver and intestine of humanized CYP3A5*3(*3) 
and CYP3A5*1(*1) mice. Data are expressed as the means ± S.D. (n = 4 mice). N.D., not detected. N.S., not 
significant. *P < 0.005.
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CYP3A5 in CYP3A4-expressing situations for drug screening. Our model mice are the first humanized Tc mice 
for the prediction of the effects of SNPs on pharmacokinetics.
The CRISPR/Cas9 system allows us to modify SNPs with high efficiency in both mouse ES cells and fertilized 
eggs (18.8% and 11% success rates, respectively). The use of mRNA and modified Cas9, eSpCas9, or SpCas9-HF1 
may increase the efficiency of such modifications by improving specificity and preventing the re-cutting of modified 
sequences29,30. In the present study, we utilized the pCAG-EGxxFP system and carefully selected a target sequence 
for SNP modification. Because evaluating whether the modified sequence is still targeted by CRISPR/Cas9 is very 
important, this system is very useful when selecting an appropriate target sequence for SNP modification.
CYP3A5 expression in the liver and intestine was higher in CYP3A5*1 mice than in CYP3A5*3 mice. Other 
CYP3A genes, particularly CYP3A4, were also expressed, and the metabolic activity was not disrupted, showing 
that designed gRNA (CYP3A5_B) was specific to CYP3A5, with no off-target effect. The CYP3A inhibition assay 
detected the contribution of CYP3A5 to CYP3A-mediated metabolism. These findings suggested that CYP3A5 
SNP was functionally modified without the disruption of any other CYP3A gene.
The CYP3A5*3 allele causes splicing defect, and participation of the nonsense-mediated mRNA decay 
has been reported to be associated with the degradation of splice variants31. However, some homozygotes of 
CYP3A5*3 allele have been reported to express the CYP3A5 protein at a low level. It is unclear how some RNA 
is spliced normally from the CYP3A5*3 allele. The effect of CYP3A5 SNP is actually recapitulated in mice. 
Therefore, it is expected to be possible to analyze the mechanism of CYP3A5 expression associated with SNPs 
using our models.
Various SNPs in CYP3A4 have been reported, but their effects have mainly been evaluated in vitro32. This is 
also relevant for MDR1, one of the most prominent and extensively studied transporters, for which polymor-
phisms have also been identified33. Despite efforts to understand the effects of MDR1 polymorphisms on phar-
macokinetics, no consensus has been reached on this issue because of the lack of a humanized animal model. 
Figure 6. Assay of triazolam hydroxylation activity in CYP3A5*1 mice. (A) Triazolam alpha-hydroxylation 
activities in liver microsomes of Cyp3a-KO and CYP3A5*1 mice. (B) Triazolam alpha-hydroxylation activities 
in intestinal microsomes of Cyp3a-KO and CYP3A5*1 mice. Data are expressed as the means ± S.E. (n = 3 
mice) of three independent assays, each performed in duplicate. N.D., not detected.
www.nature.com/scientificreports/
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Regarding the CYP2C family, the effects of CYP2C9 and CYP2C19 polymorphisms on metabolic activity toward 
drugs that are known substrates of these proteins have been reported34,35. Polymorphisms in UGT2 genes have 
also been reported to affect expression and metabolic activity36. The combined technologies, HAC/MAC and 
genome editing, developed in this study could allow us to create humanized models that reflect conditions in 
humans with different SNPs or polymorphisms with ease and speed.
A generation of Tc mice with various SNPs, starting from the development of an original human chromosome 
library harboring desired SNPs, is extremely hard and takes an excessive amount of time. The effective way for 
generation of humanized mice with desired SNPs is to modify SNPs of already constructed basic HACs/MACs 
carrying the desired human genome.
The present study effectively predicts the effect of polymorphisms on pharmacokinetics. Similar to the pro-
duction of humanized CYP3A mice, we can produce a variety of humanized model mice, such as those with SNP 
reported genes, as mentioned above, and then we can modify SNPs or polymorphisms in these humanized mod-
els to produce a useful repertoire of models. In addition, the development of humanized multiple gene models 
with defined polymorphisms can also play an important role in understanding complex pharmacokinetics.
Materials and Methods
PCR-RFLP analysis of CYP3A5 SNP. PCR-RFLP analysis was performed as described previously16. Briefly, 
PCR was performed using the following primers: CYP3A5 6956Fm, 5′-CTT TAA AGA GCT CTT TTG TCT 
CTC A-3′, and CYP3A5 7155R, 5′-CCA GGA AGC CAG ACT TTG AT-3′. PCR products were treated with DdeI 
for 2 h at 37 °C before electrophoresis using 3% agarose gel.
Plasmid construction. Sense and antisense oligonucleotides for each gRNA were annealed and inserted 
into a BbsI site of the pX330 plasmid expressing Cas9/gRNA. pX330-U6-Chimeric_BB-CBh-hSpCas9 was a gift 
from Feng Zhang (Addgene plasmid # 42230)19. Cloning of annealed oligonucleotides was confirmed by PCR 
using the following primers: human U6 promoter FW, 5′-GAG GGC CTA TTT CCC ATG ATT CC-3′, and each 
Figure 7. CYP3A inhibition assay for evaluating the CYP3A5 contribution in CYP3A5*1 mice. (A) The 
effect of ketoconazole on the triazolam alpha-hydroxylation activity in liver microsomes of CYP3A5*3 and 
CYP3A5*1 mice. (B) The effect of CYP3cide on the triazolam alpha-hydroxylation activity in liver microsomes 
of CYP3A5*3 and CYP3A5*1 mice. (C) The effects of ketoconazole on the triazolam alpha-hydroxylation 
activities in intestinal microsomes of CYP3A5*3 and CYP3A5*1 mice. (D) The effects of CYP3cide on 
the triazolam alpha-hydroxylation activities in intestinal microsomes of CYP3A5*3 and CYP3A5*1 mice. 
Pooled microsomes from four mice in each group were used. Data are expressed as the means ± S.D. of three 
independent assays, each performed in duplicate. (E) The estimation of CYP3A5 contribution in CYP3A5*3 
and CYP3A5*1 mice. N.D., not detected.
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corresponding antisense oligonucleotide. The oligonucleotides used were as follows: CYP3A5_A S, 5′-CAC CTT 
TCA GTA TCT CTT CCC TGT TTG G-3′; CYP3A5_A AS, 5′-AAA CCC AAA CAG GGA AGA GAT ACT GAA 
A-3′; CYP3A5_B S, 5′-CAC CAA GGG TAA TGT GGT CCA AAC AGG G-3′; and CYP3A5_B AS, 5′-AAA CCC 
CTG TTT GGA CCA CAT TAC CCT T-3′.
To construct the pCAG-EGxxFP validation plasmid, each target and potential off-target sequence was ampli-
fied by PCR using humanized CYP3A mouse tail DNA or synthesized DNA (Life Technologies, Carlsbad, CA, 
USA) as a template. The sequences of each primer set were as follows: C3A5 bam_L, 5′-GCT TGG ATC CAC 
CAA CTG CCC TTG CAG CAT-3′, and C3A5 ecoi_R, 5′-ACG CCG AAT TCT GGG GAC AAC GGA GCT 
GAT T-3′, for CYP3A5*1 or *3; C3A4 bam_L, 5′-GCT TGG ATC CAT GGA GAA TGG CAT GGG AAA-3′, 
and C3A4 ecoi_R, 5′-ACG CCG AAT TCC CAG CAC AGG CTG TTG ACC A-3′, for CYP3A4; C3A7 bam_L, 
5′-GCT TGG ATC CCC CAC AGC AAC TGC CCT TGA AA-3′, and C3A7 ecoi_R, 5′-ACG CCG AAT TCG 
ATC TGT GAT AGC CAG CAT AGG CT-3′, for CYP3A7; and C3A43 bam_L, 5′-GCT TGG ATC CAG CCA 
CTG CAC CCA GCC TAT-3′, and C3A43 ecoi_R, 5′-ACG CCG AAT TCA GCC TGT GTG GGG GAA AAC 
A-3′, for CYP3A43. Amplified PCR products were treated with BamHI and EcoRI and ligated to BamHI- and 
EcoRI-digested pCAG-EGxxFP plasmid.
Validation of cleavage activity. The cleavage activity of pX330-sgRNA was validated by co-transfection 
with each pCAG-EGxxFP-target plasmid into HEK293T cells, as reported previously21. pCAG-EGxxFP-Cetn1 
and pX330-sgRNA were transfected as the positive control. Only pCAG-EGxxFP-Cetn1 was transfected as the 
negative control.
SNP modification in mouse ES cells containing the CYP3A-MAC. Mouse ES cells with the 
CYP3A-MAC and the mice with the CYP3A-MAC were generated using the same method to construct mouse 
ES cells with the CYP3A-HAC and the mice with the CYP3A-HAC (Kazuki Y. et al., unpublished data)2. A total 
of 1 × 103–4 ESCs containing the CYP3A-MAC were seeded on mouse embryonic fibroblasts in a six-well plate 
and transfected with pX330-A plasmids (1.0 μg) and a donor plasmid (1.0 μg) containing a synthesized sequence 
for SNP modification (Life Technologies, Carlsbad, CA, USA), using Lipofectamine LTX & PLUS reagents (Life 
Technologies, Carlsbad, CA, USA)22. The picked clones were analyzed using PCR-RFLP.
Genomic PCR analysis. Primer pairs for the detection of a region of the human CYP3A cluster and geno-
typing of mouse-Cyp3a-KO were as described previously 2. Primer sets for the direct sequencing of the modified 
region of CYP3A5 were as follows: C3A5 int3 L, 5′-GGT GCC CTT TTA TCA CAT GCA TTG TCT C-3′, and 
C3A5 int4 R, 5′-TCA TTG GGT TGC CCA GAC TGG AGT ATA A-3′.
Ethics statement. All experimental procedures were approved by the Institutional Animal Care and Use 
Committee of Tottori University. Methods were conducted in accordance with the approved guidelines of the 
Institutional Animal Care and Use Committee of Tottori University.
Pronuclear injection. ICR female mice were superovulated and mated with CYP3A-MAC males, and fer-
tilized eggs were collected. A circular pX330-A plasmid was injected into one of the pronuclei at 5 ng/μL with 
ssODN at 100 ng/μL. The sequence of ssODN is 5′-AAC GAA TGC TCT ACT GTC ATT TCT AAC CAT AAT 
CTC TTT AAA GAG CTC TTT TGT CTT TCA ATA TCT CTT CCC TGT TTG GAC CAC ATT ACC CTT 
CAT CAT ATG AAG CCT TGG GTG GCT CCT GTG TGA GAC TCT TGC-3′.
Chimeric mouse production. Chimeric mice were produced using mouse ES cells with the 
CYP3A5*1-MAC. Briefly, ES cells were injected into eight-cell stage embryos derived from ICR mice (CLEA, 
Tokyo, Japan) and then transferred into pseudopregnant ICR females.
Humanized CYP3A5*1 mouse production. A mouse with mosaicism, with cells carrying CYP3A5*1 
or CYP3A5*3-MAC, was mated with a mouse-Cyp3a-KO mouse. The germline transmission of CYP3A5*1 or 
CYP3A5*3-MAC was monitored by EGFP expression from the MAC. Mice with the CYP3A5*1-MAC were 
further crossed with mouse-Cyp3a-KO mice. After further mating, humanized CYP3A5*1 mice were obtained.
Preparation of microsomes. Liver tissue and part of the small intestine (a 10-cm segment from the upper 
part of the small intestine) were used for the preparation of microsomal fractions.
Quantitative analysis of CYP3A5 protein by LC-MS/MS. The expressed CYP3A4 and CYP3A5 were 
digested by trypsin after reduction and cysteine blocking, after which the samples were analyzed by TOF-MS. A 
surrogate peptide from the tryptic digestion of CYP3A4 and CYP3A5 was confirmed by TOF-MS, and its charac-
teristic spectrum was collated using the protein sequence database UniProtKB/Swiss-Prot. Its identified spectrum 
as each CYP3A4 and CYP3A5 was used for constructing a measurement method by LC-MS/MS. Calibration 
curves prepared from the samples were spiked with expressed CYP3A4 and CYP3A5. Liver and intestinal micro-
somes (10 μL, 10 mg/mL) were digested in a similar manner and were quantified.
Assay of triazolam hydroxylation activities. The basic incubation mixture contained liver or intestinal 
microsomes, 100 mM potassium phosphate buffer (pH 7.4), 0.1 mM EDTA, NADPH generating system, and 200 
µM triazolam (Wako Pure Chemicals, Osaka, Japan) as a CYP3A substrate. Incubation was conducted at 37 °C for 
30 min (intestine) or 60 min (liver) and terminated by adding acetonitrile. After centrifugation, the supernatant 
was analyzed by HPLC.
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CYP3A inhibition assay. A CYP3A4/3A5 inhibitor, ketoconazole (2 µM; Sigma-Aldrich, St. Louis, MO, 
US), was co-incubated with triazolam in the reaction mixture. For CYP3A4 inhibition, microsomes were incu-
bated with triazolam for 30 min after pre-incubation with CYP3cide (2.5 µM; Sigma-Aldrich, St. Louis, MO, US), 
an inhibitor of CYP3A4, for 20 min in the reaction mixture.
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